NY1505 Novel strains of Bacillus licheniformis NY1505 producing high amount of -glucosidase inhibitors

摘要

The present invention provides Bacillus licheniformis strain NY1505 (accession number KCTC13021BP) capable of producing a large amount of -glucosidase inhibitors. Bacillus licheniformis strain NY1505, according to the present invention, is a novel strain that can survive in anaerobic conditions, and enables production and supply of -glucosidase inhibitors in the intestine, and thus shows excellent weight loss and blood glucose lowering effects by maintaining a fixed level of effective concentration. Since the Bacillus licheniformis strain NY1505 survives temporarily and does not stay in the intestine, and so the strain that has been administered when necessary or the -glucosidase inhibitors produced by the strain can be discharged, the Bacillus licheniformis strain NY1505 can be safely used. Moreover, since separate fermentation cost and processing cost are not required for the production of the -glucosidase inhibitors, the production cost can be reduced. Further, the present invention does not have the problems of fermentation odor and the like, and thus can be applied to various forms of food products.